Europe Organ-On-Chip Market Size, Share & Trends Analysis Report By Organ Type (Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, Lung on chip), By Applications (Drug Discovery, Toxicology Research, Physiological Model Development), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others) and By Country (U.K., Germany, France, Italy, Russia, Nordic, Benelux, Rest of Europe) Forecasts, 2026-2034

Europe Organ-on-Chip Market Size and Trends

The Europe Organ-On-Chip Market size was valued at USD 50 million in 2025 and is projected to grow from USD 64.05 million in 2026 to reach USD 464.42 million by 2034, growing at a CAGR of 28.1% during the forecast period 2026–2034.

In recent years, there has been a rise in regulatory support for the development of alternative experimentation methods for animal testing, which is anticipated to drive the European organ-on-chip market. Moreover, there has been a rise in research funding and collaborative efforts taken by the major stakeholders in the market to advance organ-on-chip technology for its better efficiency, thereby creating opportunities for regional market expansion.

Europe Organ-On-Chip Market Segmental Analysis

By Organ Type Insights

In terms of organ type, the liver-on-chip segment is expected to hold a prominent position in the Europe organ-on-chip market. Liver-on-chip systems are designed to reproduce selected liver functions and cellular interactions within controlled microfluidic environments, making them useful for studying drug metabolism, toxicity, and therapeutic responses.

The segment is gaining attention as pharmaceutical researchers increasingly seek human-relevant models that can complement conventional laboratory approaches. Europe's established pharmaceutical industry, advanced biotechnology ecosystem, and growing interest in reducing dependence on traditional animal testing are supporting the development and application of organ-on-chip technologies.

Other organ types, including heart on chip, human on chip, intestine on chip, kidney on chip, and lung on chip, are also expanding their applications. Heart-on-chip models can support cardiovascular research and safety assessment, while kidney-on-chip systems can be used to investigate renal function and drug-related effects. Intestine- and lung-on-chip platforms can reproduce selected tissue barriers and physiological conditions, while human-on-chip systems provide opportunities to study interactions between multiple biological systems.

Request Customizationto receive a tailored report.

By Applications Insights

Based on application, drug discovery is expected to remain a major application area in the Europe organ-on-chip market. These platforms allow researchers to examine candidate compounds under controlled biological conditions and evaluate drug responses during preclinical development.

The increasing focus on improving the relevance of preclinical research is supporting the adoption of organ-on-chip technologies across pharmaceutical and biotechnology research. Researchers can reproduce selected physiological conditions, cellular interactions, and tissue responses that may be difficult to capture through conventional cell-culture approaches. Collaboration among pharmaceutical companies, biotechnology firms, universities, and specialized technology developers is further expanding the application of these systems.

Toxicology research represents another important application, particularly for investigating potential adverse effects of pharmaceutical compounds and chemicals. Tissue-specific platforms such as liver, kidney, lung, and heart models can help researchers evaluate organ-level responses under controlled conditions. Meanwhile, physiological model development is gaining momentum as researchers create increasingly sophisticated systems for studying disease mechanisms, tissue functions, therapeutic responses, and personalized medicine.

By End-User Insights

By end-user, the Europe organ-on-chip market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others. The Pharmaceutical and Biotechnology Companies segment is expected to represent a significant area of demand as drug developers increasingly explore advanced human-relevant platforms for preclinical research.

These companies can utilize organ-on-chip systems for compound evaluation, toxicity assessment, disease modeling, and investigation of drug responses. The technology can provide more physiologically representative environments for selected stages of drug development and support research into complex biological interactions. Increasing collaboration between pharmaceutical companies, biotechnology firms, universities, and technology developers is also helping expand practical applications.

Academic and Research Institutes form another important end-user group across Europe. Universities and research centers contribute to advances in microfluidics, tissue engineering, cellular biology, disease modeling, and microphysiological systems. Their research activities are helping improve the functionality of organ-specific and multi-organ platforms.

The Others category includes specialized research organizations and emerging technology developers. As organ-on-chip platforms move toward broader commercial and research adoption, these users are expected to contribute to technology development, testing, and expansion into new biomedical applications.

Speak to an Analystto discuss market opportunities.

Europe Organ-on-Chip Market Regional Analysis

The European Organ-On-Chip market is led by Germany, the UK, France, and the Netherlands and is driven by strong pharmaceutical sectors, government funding, and research infrastructure. Germany and the UK dominate, with significant investments in OOC technology, while France and the Netherlands are emerging due to their innovation in microfluidics and biomedical research. Additionally, there has been a rise in the initiatives by researchers and academic institutes to advance organ-on-chip technology.

For instance, in April 2024, the Middle Eastern Technical University Electromechanical Systems (ODTÜ MEMS) Center researchers are currently undertaking a groundbreaking effort to create a chip that has the potential to transform pharmaceutical research by substituting animal testing. The "Strategic Partnership Focused on Organ-on-Chip Systems (OrChESTRA)" initiative, funded by the European Union's Horizon Europe program, seeks to position the MEMS Center as a prominent player in the field of organ-on-chip technology within the region.

Moreover, the market players in this region are involved in strategic initiatives to enhance their market share. For instance, in January 2024, Cambridge-based biotech companies CN Bio and Altis Biosystems collaborated to integrate Altis' RepliGut Planar-Jejunum model, an in vitro 'organ-on-a-chip' system, with CN Bio's PhysioMimix liver on a chip. The PhysioMimix liver-on-a-chip developed by CN Bio is a microphysiological system (MPS) designed to replicate the functioning of the human liver. The technologies are anticipated to eliminate the necessity for preclinical animal experiments and reduce drug development expenses. Consequently, all these factors are expected to augment the European organ-on-chip market growth.

List of Key and Emerging Players in Europe Organ-On-Chip Market